Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Vafseo Pill Approved for Adult Dialysis-Related Anemia in the US
Latest Hotspot
3 min read
Vafseo Pill Approved for Adult Dialysis-Related Anemia in the US
2 April 2024
Akebia Therapeutics Granted US Regulatory Clearance for Vafseo (vadadustat) Pills, a New Therapy for Adult Anemia Linked to Long-term Renal Failure in Dialysis Patients.
Read →
Viking Therapeutics Announces Results from First Human Trial of Oral GLP-1/GIP Dual Agonist VK2735
Latest Hotspot
4 min read
Viking Therapeutics Announces Results from First Human Trial of Oral GLP-1/GIP Dual Agonist VK2735
2 April 2024
Viking Therapeutics Reports Outcomes of Initial Human Study for Oral Pill Version of Combined GLP-1/GIP Agonist VK2735.
Read →
TiumBio Files for Phase 1b Trial of Long-Lasting Factor VII TU7710 in Hemophilia A/B Patients
Latest Hotspot
3 min read
TiumBio Files for Phase 1b Trial of Long-Lasting Factor VII TU7710 in Hemophilia A/B Patients
2 April 2024
TiumBio Lodges Application for Phase 1b Study of Prolonged-Effect Factor VII Agent TU7710 in Subjects with Hemophilia A/B.
Read →
Innovent Starts Phase III Neoshot Trial with IBI310 Plus Sintilimab in Colon Cancer
Latest Hotspot
3 min read
Innovent Starts Phase III Neoshot Trial with IBI310 Plus Sintilimab in Colon Cancer
2 April 2024
First Subject Receives Initial Treatment in Innovent's Phase III Trial (Neoshot) Evaluating IBI310 (Anti-CTLA-4) with Sintilimab in Pre-Surgery Treatment for High Microsatellite Instability/Mismatch Repair Deficient Colon Cancer.
Read →
Tectonic Therapeutics Begins Phase I Trial of TX45 for Group II Pulmonary Hypertension in Patients with HFpEF
Latest Hotspot
3 min read
Tectonic Therapeutics Begins Phase I Trial of TX45 for Group II Pulmonary Hypertension in Patients with HFpEF
2 April 2024
Tectonic Therapeutics Commences First-Stage Clinical Trial Evaluating TX45 in Category II Lung High Blood Pressure among Subjects Having Conserved Ejection Fraction Cardiac Insufficiency.
Read →
FDA Approves Merck's WINREVAIR™ for Adult Pulmonary Arterial Hypertension
Latest Hotspot
3 min read
FDA Approves Merck's WINREVAIR™ for Adult Pulmonary Arterial Hypertension
1 April 2024
FDA Regulators Greenlight Merck's Novel WINREVAIR™ (sotatercept-csrk) Therapy for Treating Pulmonary Arterial Hypertension in Adult Patients.
Read →
What is Pharmacodynamics?
"What" Series
2 min read
What is Pharmacodynamics?
1 April 2024
Pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body, including the mechanisms of action and the relationship between drug concentration and effect.
Read →
EU Approves Atamyo's ATA-200 Human Trials for Limb-Girdle MD 2C/R5
Latest Hotspot
3 min read
EU Approves Atamyo's ATA-200 Human Trials for Limb-Girdle MD 2C/R5
1 April 2024
Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.
Read →
New Opportunities in the Development of Therapeutic Drugs for Arteriosclerosis Treatment
Hot Spotlight
8 min read
New Opportunities in the Development of Therapeutic Drugs for Arteriosclerosis Treatment
1 April 2024
Gut-Derived Hormone Cholesin Found to Regulate Cholesterol Metabolism.
Read →
CinFina Pharma Gains US Approval for Early Obesity Drug Trial, Begins Dosing
Latest Hotspot
4 min read
CinFina Pharma Gains US Approval for Early Obesity Drug Trial, Begins Dosing
1 April 2024
CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.
Read →
What is Pharmacokinetics?
"What" Series
2 min read
What is Pharmacokinetics?
1 April 2024
Pharmacokinetics (PK) is the study of how a drug moves through the body, which includes the processes of absorption, distribution, metabolism, and excretion.
Read →
Japan sanctions VYLOY™ (zolbetuximab) by Astellas as a new therapeutic for stomach cancer management
Latest Hotspot
3 min read
Japan sanctions VYLOY™ (zolbetuximab) by Astellas as a new therapeutic for stomach cancer management
1 April 2024
Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.
Read →